St. Jude Medical (NYSE:STJ) once again asked physicians in a European clinical trial to stop implanting its Nanostim leadless pacemaker this year after reports of series adverse events, including perforation of the heart and dislodgment of the device.
In 1 case reported to the FDA’s adverse events database, the device became dislodged and traveled into the pulmonary artery, where it was later removed.
Help employers find you! Check out all the jobs and post your resume.
